Organovo Holdings, Lantern Pharma leads healthcare gainers, Fortress Biotech, Zynex among major losers
Gainers: Organovo Holdings (ONVO) +12%, Lantern Pharma (LTRN) +11%, Cancer Genetics (CGIX) +10%, American Well (AMWL) +10%, Immuron (IMRN) +9%.Losers: Avenue Therapeutics (ATXI) -57%, Zynex (ZYXI) -27%, Fortress Biotech (FBIO) -22%,  AgeX Therapeutics (AGE) -12%, Vaccinex (VCNX) -11%.
Seekingalpha · 10/12 14:58
Benzinga · 09/30 19:03
Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (“Organovo” or the “Company”) (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”).  On September
GlobeNewswire · 09/03 20:05
SWBI, ONVO, YRCW and PTI among midday movers
Gainers: Viveve Medical (NASDAQ:VIVE) +111%. VivoPower International (NASDAQ:VVPR) +57%. Sigma Labs (NASDAQ:SGLB) +27%. FTS International (NYSEMKT:FTSI) +2
Seeking Alpha - Article · 08/25 16:47
Wall Street Breakfast: What Moved Markets
Seeking Alpha - Article · 08/22 12:50
Organovo shares are trading lower. Not seeing any company-specific news to justify the price action.
Benzinga · 08/21 16:25
Hancock Jaffe Laboratories leads healthcare gainers: Organovo leads the losers
Gainers: Hancock Jaffe Laboratories (HJLI) +83%. Bio-Path Holdings (BPTH) +22%. Harpoon Therapeutics (HARP) +21%. Fluidigm (FLDM) +15%. Midatech Pharma (MTP) +13%.Losers: Organovo (ONVO) -10%. Akers Biosciences (AKER) -9%. Trevena (TRVN) -9%. OpGen (OPGN) -9%. Axcella Health
Seekingalpha · 08/21 15:03
Organovo Announces One-for-Twenty Reverse Stock Split
SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its
GlobeNewswire · 08/17 13:05
Organovo to reverse split shares 1:20
Aimed at regaining Nasdaq compliance of minimum bid price requirement for continued listing, Organovo Holdings (ONVO) will execute a 1-for-20 reverse split of its common stock at 5:00 pm ET on August
Seekingalpha · 08/17 12:57
Organovo Announces One-For-Twenty Reverse Stock Split
Benzinga · 08/17 12:07
66 Biggest Movers From Thursday
Gainers GEE Group, Inc. (NYSE: JOB) shares climbed 199.9% to close at $1.54 on Thursday after the company eliminated over $47 million in debt and mezzanine financing.
Benzinga · 07/06 09:18
Hedge Fund Sentiment Is Stagnant On Organovo Holdings Inc (ONVO)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These fi
Insider Monkey · 06/10 19:43
The Top Stocks To Buy Now
Seeking Alpha - Article · 05/09 00:41
Organovo Up On Cancelled Merger, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 04/09 11:52
The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO
Benzinga · 04/08 12:53
The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
Benzinga · 04/08 11:53
Edited Transcript of ONVO earnings conference call or presentation 9-Nov-17 10:00pm GMT
Thomson Reuters StreetEvents · 04/08 07:43
Organovo stockholders nix Tarveda merger; shares up 2% after hours
seekingalpha · 04/08 01:38
Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics
Business Wire · 04/07 21:12
Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda Therapeutics
GlobeNewswire · 04/02 12:00
Webull provides a variety of real-time ONVO stock news. You can receive the latest news about Organovo Holdings through multiple platforms. This information may help you make smarter investment decisions.
About ONVO
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.